Table 1.
Frequency of RET biomarkers in vandetanib Phase III NSCLC trial program
| Clinical study | RET biomarker, n (%) [95% CI] | |||||||
|---|---|---|---|---|---|---|---|---|
| RETrearrangement | RETamplification | LowRETgene copy number gain | RET expression | |||||
| Van | Comp | Van | Comp | Van | Comp | Van | Comp | |
| ZODIAC + ZEAL | 1 | 2** | 6 | 7 | 14 | 14 | 16 | 24 |
| ZEPHYR | 2 | 1 | 2 | 3 | 19 | 5 | 18 | 10 |
| ZEST | 0 | 1** | 4 | 2 | 8 | 14 | 12 | 10 |
| Untreated* | – | 2 | 2 | 2 | ||||
| Non-Asian | 5/632 (0.8) | 19/632 (3.0) | 49/632 (7.7) | 52/756 (6.9) | ||||
| [0.3–1.8] | [1.8–4.6] | [5.7–10.0] | [5.2–8.9] | |||||
| Asian | 2/305 (0.7) | 7/305 (2.3) | 27/305 (8.8) | 40/346 (11.6) | ||||
| [0.1–2.3] | [0.9–4.6] | [5.9–12.5] | [8.4–15.4] | |||||
| Overall | 7/937 (0.7) | 26/937 (2.8) | 76/937 (8.1) | 92/1102 (8.3) | ||||
| [0.3–1.5] | [1.8–4.0] | [6.4–10.0] | [6.8–10.1] | |||||
Comp, comparator; Van, vandetanib. *One patient randomized to ZODIAC and one randomized to ZEAL did not receive treatment. **One RET rearrangement with an unknown, non-KIF5B fusion partner was identified in the ZEAL comparator and one was identified in the ZEST comparator arm.